Industry News
Biotechnology Industry News
Steven Hatfill, a senior advisor…
Steven Hatfill, a senior advisor for biosecurity at the Department of Health and Human Services, has been terminated from HHS “for cause,” an agency spokesperson confirmed to Fierce Biotech.
Eli Lilly has halted development…
Eli Lilly has halted development of a phase 2 P2X7 inhibitor for pain in the latest shakeup to a pipeline that has already seen significant pivots this year.
Bristol Myers Squibb is shedding…
Bristol Myers Squibb is shedding two clinical programs from its in-house pipeline, one from its 2023 Mirati buyout and another from a partnership with U.K. biotech Exscientia, now known as Recursion.
Inflammation biotech Evommune…
Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price between $15 and $17 per share.
Sensei Biotherapeutics is…
Sensei Biotherapeutics is abandoning its sole clinical-stage drug and warning of imminent layoffs as the company mulls its options.
Takeda has given up on an…
Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study.
Novo Nordisk has thrown a…
Novo Nordisk has thrown a curveball at Pfizer by attempting to outbid the U.S. pharma for the obesity biotech Metsera.
After Intellia Therapeutics paused…
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the FDA has made things official by placing the studies under a clinical hold.
Boehringer gave no hint of the…
Boehringer gave no hint of the small molecule’s modality or what indications it will be tested against first.
Roche has headed back to China to…
Roche has headed back to China to pen a licensing deal worth more than $1 billion biobucks for the rights to a clinical-stage bispecific antibody for respiratory diseases.
Roche’s Genentech unit is laying…
Roche’s Genentech unit is laying off staff at its Bay Area headquarters for the third time this year, saying goodbye to 118 employees in a workforce reduction that spans multiple departments.
SVP David Burnham outlines how…
SVP David Burnham outlines how payer engagement, digital innovation and patient-centric design are reshaping clinical trials and accelerating development timelines.
Startup’s hybrid AI system aims…
Startup’s hybrid AI system aims to reduce documentation bottlenecks and accelerate drug development timelines across the pharmaceutical industry.
AbbVie has scrapped an asset from…
AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for the Chicago pharma confirmed to Fierce Biotech.
Novartis is pulling back the…
Novartis is pulling back the curtain on late-stage Sjögren’s wins, revealing an edge for its investigational monoclonal antibody ianalumab over placebo in both studies.
Regeneron is buying into Modex…
Regeneron is buying into Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion.
Amgen Ventures-backed AAVantgarde…
Amgen Ventures-backed AAVantgarde Bio has raised $143 million in series B funding that the Italian biotech will use to push its two AAV gene therapies for eye diseases through the clinic.
Kyverna Therapeutics has reported…
Kyverna Therapeutics has reported deep, sustained improvements in autoimmune disease patients who received a single dose of its CAR T-cell therapy KYV-101.
GSK once dreamed of harnessing the…
GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. But that dream appeared to die this morning as the pharma closed the last programs related to this
BridgeBio Pharma is having a…
BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another late-stage rare disease win as it eyes an FDA review in 2026.